Global Organ on Chip Market Size, Share, and COVID-19 Impact Analysis, By Offering (Product, Services), By Organ Type (Lung, Liver, Heart, Kidney & Others), By Application (Drug Discovery, Disease Modelling, Customized Medicines, Toxicology Research, Others), By End User (Pharmaceutical, Biotechnology, Academic, Research Institutes, Others) and by Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa) Analysis and Forecast 2022-2028

KEY MARKET INSIGHTS

The global organ on chip market was valued at USD 103.4 Mn in 2021. The market is projected to grow USD 173.3 Mn in 2028, at a CAGR of 31.5%. Organ on chips have proven to be incredibly useful systems for disease modelling, medication testing, and organ function imitating. This organ-on-a-chip methodology allows you to develop devices for liquid perfusion with controlled inner and exterior geometries that can simulate blood flow and re-create organ systems. The surge in the application of growing emphasis on developing alternatives for animal testing models, a substantial increase in research funding for organ-on-chip growth, an increasing number of partnerships and collaborations between pharmaceutical companies and organ-on-chip manufacturers, and a growing need for early drug detection are all major factors driving the growth of the organ on chip market size.

COVID-19 ANALYSIS

The COVID-19 outbreak is expected to boost the market for organs-on-chips. A large number of biotechnology and pharmaceutical around the world have been reconfigured to boost hospital application for COVID-19 patients. Due to the substantial increase in COVID-19 cases, non-essential procedures may face a backlog. Manufacturing and shipping of healthcare essentials were both disrupted as a result of the shutdown. During the COVID-19 pandemic, however, organ-on-chip technology emerged as a potential tool for the creation of medications and vaccines that were being researched and tested for the virus. As a result, it had a hugely favorable impact during the pandemic. Because of the significant number of coronavirus positive patients in healthcare institutions, such as pharmaceutical, many countries have postponed elective operations and other healthcare procedures indefinitely. Furthermore, demand for home healthcare services is rising among the elderly, who are at a higher risk of contracting an illness and are unable to visit a healthcare facility. Governments all over the world have issued laws, regulations, and protocols that enterprises must follow in order to resume manufacturing. For instance, in October 2020, The US Food and Drug Administration signed a collaboration with Emulate Inc. in October 2020 to assess the safety of COVID-19 vaccinations and protective immunity against SARS-CoV-2 using lung-chips.

LATEST TREND

Growing Demand of Drug Development to Propel Growth for Organ On Chip Market

The increasing applications of drug developments including target validation, biomarker identification & validation, compound optimization, and preclinical safety assessment. Recent advancements in the differentiation of human induced pluripotent stem cells (hiPSCs) promise an endless supply of human generated heart cells from both healthy and diseased populations. Aforementioned factors are likely to anticipate the growth of the global organ on chip market.

DRIVING FACTORS

Growing Demand of Miniaturization of Electronic Chips

The growing prevalence for microchips is a result of technological advancement that propel the growing demand for medical devices. The miniaturization minimizes the quantity of materials required to construct and maintain the system. Additionally, miniaturized tissues are cultivated on microfluidic chips to simulate real tissue in organ on a chip system. The underlying premise is to create an in vitro environment at the scale of microns that mimics the function or structure of an organ.

Rising Healthcare Expenditure in Developed Countries

The rising prevalence of chronic diseases and elderly patient population are expected to drive up demand for the market growth. Additionally, rising healthcare expenditures in many countries are expected to fuel the market in the approaching years. As a result, an increase in the number of patients is expected to drive up product demand over the projection period. For instance, in February 2019, according to a report of World Health Organization (WHO) on global health expenditure, it has been observed that there is a rapid upward trajectory on healthcare expenditure particularly noticeable in low and middle income countries, where health spending is growing on an average of 6% annually, compared to 4% in high-income countries.

RESTRAINTS

Concerns Pertaining due to High Cost of Organ Chip Device

However, the costly cost of the organ chip device, as well as the fact that organ-on-chip (OOC) technology is still in its early stages, is projected to limit market expansion. Certain countries are not allowed to perform cosmetic testing on animals is likely to hamper the growth of the global organ on chip market. Animal testing of cosmetics developed in the country has been prohibited by the government.

SEGMENTATION

The global organ on chip market is segmented by Type (Product, Services), By Organ Type (Lung, Liver, Heart, Kidney & Others), By Application (Drug Discovery, Disease Modelling, Customized Medicines, Toxicology Research, Others), By End User (Pharmaceutical, Biotechnology, Academic, Research Institutes, Others) and Region. Based on the type, the market is categorized into product, services. Based on organ type, the market is categorized into lung, liver, heart & others. Based on application, the market is categorized into Drug Discovery, Disease Modelling, Customized Medicines, Toxicology Research. Based on end user, the market is categorized into pharmaceutical, biotechnology, academic, research institutes, xx, others. Based on the region, the market is categorized into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

REGIONAL INSIGHTS

The global organ on chip market is categorized into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. North America region is expected to dominate the market share of global organ on chip market owing to the The presence of key pharmaceutical companies, as well as the availability of new and advanced organs-on-chips models on the market, favourable government initiatives in terms of funding and programmes for basic drug development and research, and the availability of new and advanced organs-on-chips models on the market. Increased incidence of targeted diseases such as UI, bladder blockage, urine retention, Benign Prostate Hyperplasia (BPH), and bladder cancer is driving the regional market. As a result, the market in North America is being driven by an increase in the number of BPH-related surgical procedures and an increase in the number of occurrences of bladder cancer. However, Asia Pacific is anticipated to be the fastest-growing regional market during the forecast period. The regional market is being driven by the countries like China, India, and Japan offer attractive opportunities. Furthermore, as the population's disposable income rises, the region's adoption of Organ-on-a-Chip technology is likely to rise. The expansion of the Organ-on-a-Chip market in the Asia-Pacific region is predicted to be aided by government support for regenerative medicines in research institutions, as well as an increase in the number of cell-based clinical trials and investment in R&D activities.

INDUSTRY PLAYERS

• Altis Biosystems
• AxoSim Inc.
• Bi/ond
• BiomimX SRL
• Elveflow
• Emulate Inc.
• Hesperos
• Hurel Corporation
• Allevi Inc.
• InSphero AG
• MIMETAS BV
• Kirkstall Ltd
• NETRI
• Nortis Inc.
• TARA Biosystems Inc.
• TissUse GmbH

KEY INDUSTRY DEVELOPMENTS:

April 2022- NETRI launches its new organs-on-chip container, called NeoBento which offers an optimized user experience, in terms of handling and possibilities, chip assortment, compatibility, readouts amongst others.

February 2022- Researchers from MIMETAS and Astellas introduce OrganoPlate® 3-lane 40, a combination human renal proximal tubule/blood vessel-on-a-chip model to study acute kidney damage (AKI) caused by renal ischemia/reperfusion injury (rIRI). Kidney360 has recently published this story.

December 2021- Emulate, Inc. has announced that its Brain-Chip will be sent to the International Space Station U.S. National Laboratory (ISS National Lab) to study the effects of microgravity on human brain physiology (ISS-NL).

November 2021- TARA Biosystems collaborated with Scipher Medicine to address a critical unmet need for effective therapeutics in cardiac laminopathies.

August 2021- InSphero AG announced that the company is making their proprietary, patented 96- and 384-microwell plates available to researchers, enabling them to access the same plate technology used in the company’s flagship, assay-ready 3D InSight Human Liver Microtissues.

March 2021- AIM Biotech has launched a contract research service, which uses its organ-on-a-chip technology to accelerate and improve drug discovery and development.

SEGMENTATION 

By Offering

Based on offering, is categorized into product, services. The product segment is expected to dominate the market share of global organ on chip market owing to increased number of key players and growing number of partnerships and collaboration between pharmaceutical companies and organs-on-chips manufacturers as a result of technology breakthroughs and new product releases.

By Organ Type

Based on organ type, the market is categorized into lung, liver, heart, kidney & others. The lung segment is expected to dominate the market share of global organ on chip market owing to lower lung transplants have led to the development of lab-engineered chips that replicate their functions and are used to screen drugs for respiratory illnesses. Lung-on-chip also offers a unique in vitro approach to drug screening by imitating the intricate mechanical and biochemical behaviours of a human lung, thanks to the combination of micro manufacturing techniques and contemporary tissue engineering.

By Application

Based on application, the market is categorized into drug discovery, disease modelling, customized medicines, toxicology research, others. The drug discovery is expected to dominate the market share of global organ on chip market. The significant increase in demand for early detection of drug toxicity is also playing crucial role in the demand of drug discovery.

By End User

Based on end user, the market is categorized into pharmaceutical, biotechnology, academic, research institutes, others. The pharmaceutical segment is expected to dominate the market share of global organ on chip market owing to increasing applications of drug discovery including target validation, biomarker identification & validation, compound optimization, and preclinical safety assessment.

By Region

• North America- U.S., Mexico, Canada
• Europe- UK, France, Germany, Italy
• Asia-Pacific- China, Japan, India
• Latin America- Brazil, Argentina, Colombia
• The Middle East and Africa- United Arab Emirates, Saudi Arabia